Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
- PMID: 32102521
- PMCID: PMC7332123
- DOI: 10.31557/APJCP.2020.21.2.431
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique
Abstract
Background: Up to half of the heritable mutations in breast cancer (BC) are attributed to BRCA1 and BRCA2 genes. The mutation prevalence is variable based on ethnicity and may be influenced by founder mutations. The aim of this pilot study is to determine for the first time, the prevalence of BRCA1 5382insC founder mutation in a cohort of Egyptian familial breast cancer patients (FBC).
Methods: Female patients were selected to have familial type of breast cancer. Twenty healthy females were included as a control group. Peripheral blood samples were withdrawn from all studied females and were analyzed for BRCA1 5382insC founder mutation detection using pyrosequencing technique.
Results: Eighty Egyptian FBC females were eligible to be enrolled in the study with a mean age of 48.31 ± 10.97years.We found a BRCA1 5382insC mutation carrier frequency of 5% of total studied FBC patients (4 out of 80 patients) with 95% confidence interval (1.61-12.99). There was a high statistical significant difference between carriers and non-carriers concerning the number of affected family members by BC, (p=0.001). Conclusion: BRCA1 5382insC founder mutation is not uncommon among Egyptian FBC females. The carrier frequency is comparable to that reported worldwide; however it is lower than those from previous Egyptian studies using different molecular techniques. The strong association between the mutation and the number of affected family members suggest wider screening of the mutation among high risk families using the reliable pyrosequencing technique.
Keywords: BRCA 1 mutation; Pyrosequencing technique; familial breast cancer.
Figures


Similar articles
-
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer.Oncol Ther. 2023 Dec;11(4):445-459. doi: 10.1007/s40487-023-00240-9. Epub 2023 Sep 20. Oncol Ther. 2023. PMID: 37731153 Free PMC article. Review.
-
The BARD1 Cys557Ser variant and breast cancer risk in Iceland.PLoS Med. 2006 Jul;3(7):e217. doi: 10.1371/journal.pmed.0030217. PLoS Med. 2006. PMID: 16768547 Free PMC article.
-
Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17. Eur J Surg Oncol. 2015. PMID: 25736863
-
Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran.Asian Pac J Cancer Prev. 2013;14(7):4339-45. doi: 10.7314/apjcp.2013.14.7.4339. Asian Pac J Cancer Prev. 2013. PMID: 23992000
-
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.Lancet. 1997 May 24;349(9064):1505-10. Lancet. 1997. PMID: 9167459
Cited by
-
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4. BMC Cancer. 2022. PMID: 35216584 Free PMC article.
-
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer.Oncol Ther. 2023 Dec;11(4):445-459. doi: 10.1007/s40487-023-00240-9. Epub 2023 Sep 20. Oncol Ther. 2023. PMID: 37731153 Free PMC article. Review.
-
Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience.Front Genet. 2022 Apr 8;13:834265. doi: 10.3389/fgene.2022.834265. eCollection 2022. Front Genet. 2022. PMID: 35464868 Free PMC article.
References
-
- Abdel-Mohsen MA, Ahmed OA, El-Kerm YM. BRCA1 gene mutations and influence of chemotherapy on autophagy and apoptotic mechanisms in Egyptian breast cancer patients. Asian Pac J Cancer Prev. 2016;17:1285–92. - PubMed
-
- Abou-El-Naga A, Shaban A, Ghazy H, et al. Frequency of BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) mutations in Egyptian women with breast cancer compared to healthy controls. Meta Gene. 2018;15:35–41.
-
- Backe J, Hofferbert S, Skawran B, et al. Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol. 1999;72:402–6. - PubMed
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous